Reboxetine is a selective noradrenaline reuptake inhibitor (not totally selective, a slight serotonin reuptake inhibition is seen at clinical doses), that according to at least one systematic review is ineffective and potentially dangerous, whereas according to one it is effective and safe.:378-380 It has never been approved by the FDA, although it is used in the remainder of the developed world (including Australia, the U.K., Germany, New Zealand, etc.), aside from Canada and Singapore. It is taken twice a day and has been used off-label for the treatment of ADHD, obesity, panic disorder, narcolepsy and potentially, cocaine dependence. Its principal side effects include urinary problems (like difficulty passing urine) and side effects you would expect for a sympathomimetic, such as insomnia, anti-parasympathomimetic effects like dry mouth, constipation, blurred vision, etc.; increased sweating, high heart rate, hypertension, etc.